An Exploratory, Proof-of-Concept, Early-Stage, Randomized, Double-Blind, Vehicle and Active Controlled, Intra-Individual, Phase I/II Study to Evaluate the Safety and Efficacy of SNA-125 Gel for Treatment of Atopic Dermatitis
Phase of Trial: Phase I/II
Latest Information Update: 03 Dec 2018
At a glance
- Drugs SNA 125 (Primary)
- Indications Atopic dermatitis
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Sponsors Sienna Biopharmaceuticals
- 03 Dec 2018 Status changed from active, no longer recruiting to completed.
- 03 Dec 2018 Results presented in a Sienna Biopharmaceuticals media release.
- 27 Aug 2018 Status changed from recruiting to active, no longer recruiting, according to a Sienna Biopharmaceuticals media release.